Viking Therapeutics

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Viking Therapeutics' research and development efforts leverage the company's expertise in metabolism to advance innovative treatments that improve patients' lives. The company's lead clinical program is VK0612, a first-in-class oral drug candidate for type 2 diabetes. The company’s second clinical program is VK5211, an oral, non-steroidal selective androgen receptor modulator (SARM) for the treatment of cancer cachexia. Viking Therapeutics is also advancing three new preclinical programs targeting metabolic diseases and anemia.